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Abstract 
 The CAGI-4 Hopkins clinical panel challenge was an attempt to assess state of the art 
methods for clinical phenotype prediction from DNA sequence.  Participants were provided with 
exonic sequences of 83 genes for 106 patients from the Johns Hopkins DNA Diagnostic Laboratory.  
Five groups participated in the challenge, predicting both the probability that each patient had each 
of fourteen possible classes of disease, as well as one or more causal variants.  In cases where the 
Hopkins laboratory reported a variant, at least one predictor correctly identified the disease class in 
36 of 43 patients (84%).  Even in cases where the Hopkins laboratory did not find a variant, at least 
one predictor correctly identified the class in 39 of 63 patients (62%).  Each prediction group 
correctly diagnosed at least one patient that was not successfully diagnosed by any other groups. 
We discuss the causal variant predictions by the different groups and their implications for further 
development of methods to assess variants of unknown significance.  Our results suggest that 
clinically relevant variants may be missed when physicians order small panels targeted on a specific 
phenotype.  We also quantify the false positive rate of DNA-guided analysis in the absence of prior 
phenotypic indication. 
Key Words: variant interpretation, genetic testing, phenotype prediction, CAGI 
Introduction 
DNA sequencing tests are increasingly used in medical practice to confirm or assign clinical 
diagnoses (Katsanis and Katsanis, 2013).  However, the interpretation and classification of novel 
sequence variants identified in a patient remains difficult, even for well-studied disorders like cystic 
fibrosis (Sosnay et al. 2017).  Improved computational methods may aid in the interpretation of 
sequence variants and, when used in conjunction with clinical data, could increase the confidence of 
a diagnosis (Schulz et al. 2015).  Until recently, genetic testing was limited to genes associated with a 
specific clinical phenotype.  However, recent technological advances have made it feasible to 
sequence large gene panels, exomes, and genomes (Lee et al. 2014, Posey et al. 2016, Vassy et al. 
2014).  As the number of genes sequenced per patient increases, the number of novel, rare, and 
unclassified variants also increases.  Clinical molecular geneticists must determine which variants, if 
any, are likely to contribute to the patient’s clinical presentation.  The current gold standards for 
assessing a variant’s pathogenicity are segregation of the variant with the clinical phenotype in 
multiple pedigrees, and functional assays demonstrating a detrimental effect of that specific 
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nucleotide change.  In most instances, when a novel genetic variant is identified there is no rapid 
and reliable method to assess its pathogenicity.  Predictive software tools are interrogated, but none 
are considered strong evidence to assert a novel variant’s pathogenicity (Richards et al. 2015).  The 
shift towards analyzing large datasets has led to a need for high-throughput methods to aid in 
variant classification and also for computation tools to help better interrogate the increasing 
number of variants of uncertain clinical significance. 
Crowdsourced data analysis challenges such as the 4th Critical Assessment of Genome 
Interpretation (CAGI-4) have emerged as a framework to compare predictive methods and assess 
the overall state of particular analysis areas (Saez-Rodriguez et al., 2016).  In the CAGI-4 Hopkins 
Clinical Panel challenge, participants were asked to develop or use existing computational methods 
to analyze data from a next generation sequencing (NGS) panel in order to match a patient’s 
genotype to their clinical phenotype in the absence of additional clinical information. The Johns 
Hopkins DNA Diagnostic Laboratory (henceforth, Hopkins), a CLIA and CAP certified lab that 
specializes in clinical molecular testing for rare, inherited disorders, provided data for this challenge.  
The Hopkins lab offers testing for approximately 50 phenotypes and disorders totaling 3,500 tests 
annually.  They offer NGS-based tests targeted for ~20 specific phenotypes. The same NGS capture 
probe set is used for all panels and only the requested genes are analyzed in each patient.  Hopkins 
provided CAGI-4 organizers with the VCF files for the entire NGS panel for 106 patients with a range 
of clinical presentations.  The genetic disorders associated with variants in the 83 genes on the panel 
were grouped into 14 ‘disease classes’ which include lung disorders, peroxisomal disorders, 
aneurysm disorders and craniofacial disorders (Table 1, Supp. Table S-4).  The goal of the challenge 
was for the participants to match each patient to a disease class based on informatics analysis of the 
sequence data.  A further part of the challenge was to predict the specific gene and variant(s) that 
is/are the underlying cause of disease. 
Materials and Methods 
Sequencing, variant calling, and analysis by the Hopkins lab 
Gene sequences were captured using one of two custom probe sets (Agilent SureSelectXT 
Target Enrichment Kit) and sequenced by a NGS platform (Illumina MiSeq, 2x100 nt reads).  The NGS 
panels used to test assessed exons and exon-adjacent sequences for 64 or 83 loci (Supp. Table S-4, 
Supp. Table S-5). Sequences were aligned to the human reference genome (GRCh37/hg19) using the 
Burrows-Wheeler Aligner (bwa).  Sequence variants were called individually for each patient to 
produce two Variant Call Format (VCF) files, one for single nucleotide variants (SNVs; GATK 
UnifiedGenotyper, v2.7-4) and one for insertion-deletion variants (InDels; GATK HaplotypeCaller, 
v2.7-4).  Deidentified VCF files were provided to the CAGI-4 organizers.  Note that the CAGI-4 
organizers combined individual VCF files for each patient into a single VCF, resulting in potentially 
misleading data in the INFO and FILTER fields of the file. The panel of 83 genes was sequenced in 96 
of the 106 patients; for the other 10 patients, a partially overlapping list of 64 genes were sequenced 
(Supp. Table S-5).  Although the whole NGS panel was sequenced in all patients, only the genes 
selected on the patient’s test requisition form were analyzed by the lab (n=1-24 genes/patient).  For 
more information on the specific NGS tests offered by the lab refer to the Hopkins lab website 
(http://www.hopkinsmedicine.org/dnadiagnostic/tests/).  The Hopkins lab included variants in the 
genes they analyzed that were classified as Variants of Uncertain Significance (VUS), Likely 
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Pathogenic, and Pathogenic as an answer key.  The disease class of each patient was also provided in 
the answer key and reflects the test selected by the patient’s physician on the test requisition form.  
The ~20 phenotypes that Hopkins tests for were narrowed down to 14 disease classes in order to 
simplify the challenge (Supp. Table S-1).  Some disease classes were not represented by any patients 
and were included as red herrings (Supp. Figure S-9). 
Challenge format 
 Participants in the Hopkins clinical panel challenge were provided with the two VCF files 
above, a detailed description of the 14 disease classes given in Table 1, a submission template, a 
submission validation script, and the gene capture regions used in sequencing the patients (in 
Browser Extensible Data, or BED format).  Participants were also instructed that every patient 
matched exactly one disease class. 
Participants were asked to submit predictions of each patient’s disease class based on their 
gene panel sequences, along with predicted causal variant(s).  Each participant was allowed to 
submit up to six distinct submissions, in which each submission contained predictions for each 
patient.  For each submission, participants were required to predict the probability that the patient 
has a referring disease in each of the 14 disease classes in the provided list, as well as the predicted 
causal variant(s) from the gene panel sequence dataset for every disease class with a non-zero 
probability.  Each predicted probability of disease class also included a mandatory standard 
deviation (SD) field indicating confidence in the prediction, with low SD indicating high confidence, 
and high SD indicating low confidence.   
Assessment 
 Formatting errors in all submissions were corrected to the best of the assessor’s ability, and 
redundant submissions were removed.  Predicted disease classes made in each submission for each 
patient were assessed against the correct disease class given in the Hopkins answer key, using the 
metrics described below.  The predicted causal variant(s) were also compared to interpretations 
from the clinical laboratory, but because these are not known with certainty, such predictions 
cannot be rigorously assessed.  In their answer key, Hopkins noted which variants they regarded as 
Variants of Uncertain Significance (VUS), Likely Pathogenic, and Pathogenic; however, for purposes 
of matching participants’ predictions to the answer key, all variants noted by Hopkins for each 
patient were treated equivalently. 
Assessors first calculated the number of correct predictions of disease class made in each 
submission.  For each patient, the predicted disease class was the one assigned the highest 
probability among all 14 disease classes.  Ties (i.e., cases where multiple disease classes were all 
assigned the highest probability) were handled as described below. 
1) If all 14 probabilities for a patient were equal (e.g., all zeroes), those predictions were not 
counted in the following three metrics. 
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2) In other cases, assessors calculated one metric (nCorrect) in which the number of correct 
predictions was counted, giving ties full credit; another metric (nCorrecttie) was calculated in 
which N-way ties were given 1/N credit. 
3) Finally, assessors calculated a third metric (nCorrectvar) in which they counted the number of 
predictions for which the disease class was correct (giving ties full credit) AND for which at 
least one of the variants submitted in the corresponding column for that disease class matched 
one of the variants noted by Hopkins. 
 
Assessors also calculated the following metrics for each submission: 
1) avgPCorrect – the average probability assigned by the predictor to the correct disease class.  
This statistic provides an assessment of predictions that is not dependent on whether the 
submitter’s highest probability prediction was correct. 
2) avgPCorrectnorm– the average probability assigned by the predictor to the correct disease class, 
after normalizing all probabilities predicted in each submission for each patient to sum to 1.0.  
(Exception: if all probabilities for a patient were zero, they were not normalized). 
3) avgRank – the average rank assigned by the predictor to the correct disease class.  Ties were 
assigned the average rank of each set of tied predictions; e.g., if the two highest probability 
disease classes had equal rank, both were assigned a rank of 1.5; a 3-way tie for 2
nd
 highest 
probability would be assigned a rank of 3.  Note that because there were 14 disease classes, an 
all-zero prediction would have an avgRank score of 7.5 (i.e., was scored as a 14-way tie). 
4) avgError – the average error in predictions, where the error was measured as the absolute 
difference between the probability assigned each disease class and zero (if not the correct 
disease class) or one (if the correct disease class).  Like avgPcorrect, avgError assesses 
predictions independent of their rank, but also includes correct negative predictions. 
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Prediction Methodology 
A summary of each group’s prediction methods is given below. 
Group 57 (Jones) 
The Jones-UCL group made use of one-class Support Vector Machine (SVM) classifiers to 
automatically assign disease classes according to the supplied exome data.  In a normal machine 
learning experiment, sufficient positive and negative cases are needed to define a hypersurface 
which separates the two classes.  Standard SVMs attempt to define this hypersurface such that the 
chance of misclassifying new cases is minimized.  In some applications, however, only positive or 
negative cases are readily available, but not both.  One-class SVMs (Schölkopf et al. 2001) have been 
proposed for problems where either negative or positive case data is unavailable.  In this situation, 
the SVM attempts to identify outliers from a distribution modeled on the available single class of 
data, and it is assumed that the outliers belong to the alternative class. 
 
In this CAGI challenge, of course, neither negative nor positive training data was readily 
available.  However, the assumption was made that the 1000 Genomes data set (1000 Genomes 
Project Consortium et al. 2010) could be used as a proxy for negative case data.  This is a reasonable 
assumption if we assume that the diseases in question are relatively rare.  To start with, gene 
variants relating to each disease class were collated using ClinVar (Landrum et al. 2016).  Feature 
sets were generated for each disease class by encoding variant 0/0, 0/1 and 1/1 calls as 0, 1 and 2 
respectively, and for each disease-specific feature set, a one class ν-SVM (using a RBF kernel) was 
trained.  The single parameter ν, which controls both the number of support vectors and the 
misclassification cost, was optimized for each disease class so as to minimize the number of outliers 
detected in the 1000 Genome training data.  Once trained, the SVM was then applied to the test 
sample data, and the distance to decision boundary was used as a proxy for classification 
confidence.  The most important variant was identified in each case by systematically removing each 
variant from the feature set and recalculating the confidence scores. 
 
Group 58 (Tosatto) 
The analysis started with a manually curated association between the genes of the panel and 
the 14 clinical phenotypes of interest based on literature review. Sequencing data was annotated 
with ANNOVAR (Wang et al. 2010),  considering for each variant the corresponding affected gene, 
frequency estimated from the 1000 Genomes Project (Consortium 2012) and predicted 
pathogenicity score from SIFT (Ng and Henikoff 2003) and PolyPhen2 (Adzhubei et al. 2013). The 
method to define association between genetic data and phenotypes was based mainly on two 
phases. For each individual, variations that are less probable to be disease causing were filtered out 
and a probability to be affected based on the analysis of variants defined. Only coding and splice-site 
variants which can affect protein function were considered according to the Common Disease-Rare 
Variant Hypothesis (CDRVH) (El-Fishawy 2013). Common (MAF > 5%) and/or synonymous single 
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nucleotide variations (SNVs) were filtered out. Insertion and deletions were excluded as their impact 
on protein function is difficult to predict compared to SNVs.  Only insertions and deletions (indels) 
affecting the coding part of a gene and predicted to be “damaging” or known to be pathogenic were 
considered. Heterozygous indels in genes with autosomal recessive inheritance, occurring in GC-rich 
or repeated regions were filtered out from the disease candidate mutation pool.  An empirically 
derived scoring scheme was implemented to define association between patients and phenotypes, 
considering both disease inheritance and predicted SNV pathogenicity (Supp. Table S-2).  Different 
weights were assigned to different mutation types, i.e. a high score for known variants associated 
with a specific disease (mainly by literature review) and a lower score for mutations not affecting 
protein function according to predictor output (i.e. tolerated, benign and unknown).  For autosomal 
dominant (AD) pathologies, only heterozygous variants plus few manually curated homozygous 
mutations were considered (i.e. the one with the highest probability score). The disease cutoffs were 
set at different values between submissions, allowing the stringency of the analysis to vary.  Both 
homozygous and compound heterozygous variants were considered for autosomal recessive (AR) 
conditions. When more than one match per patient occurred, only the most likely was considered 
(e.g. the one with higher probability score).  Different submissions correspond to different sets of 
weights.  
 
In particular, in the first submission, a slightly lower weight was assigned to variants whose 
effect is more difficult to assess (i.e. compound heterozygous, homozygous variants with uncertain 
significance, variants affecting different genes coding for subunits of the same complex) with respect 
to submission 4.  
 
Group 59 (Qiagen Bioinformatics) 
All 106 samples were uploaded to Ingenuity Variant Analysis (QIAGEN- Hereditary Disease 
Solution) and set up an analysis with all samples to filter low quality (call quality < 20) and common 
variants (>0.5% MAF in 1000 Genomes (1000 Genomes Project Consortium et al. 2010), NHLBI-EVS 
(http://evs.gs.washington.edu/EVS/), ExAC (Consortium et al. 2016), and Allele Frequency 
Community (www.allelefrequencycommunity.org), using the Confidence and Common Variants 
filters, respectively.  The Allele Frequency Community is a QIAGEN hosted allele frequency database, 
founded by QIAGEN and participating members in 2014.  It is a freely accessible “opt-in” community 
resource designed to facilitate sharing of anonymized, pooled allele frequency statistics among 
community members.  The Predicted Deleterious filter was used to keep only those variants that are 
previously published and classified Pathogenic or Likely Pathogenic, using ACMG guidelines, DM 
variants (pathological mutations reported to be disease causing in the original literature report) 
present in HGMD, along with other loss of function (frameshift, start/stop loss or gain, splice site) 
and missense variants.  Finally, the biological context filter was applied to find variants linked to each 
one of the 14 categories and patient disease category was predicted based variant-disease 
connection, using path-to-phenotype evidence. 
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Group 60 (RSS) 
Gene phenotype associations were mined from the Hopkins diagnostic panels, OMIM 
(Hamosh et al. 2005), and GeneReviews (Pagon et al. 1993).  Inheritance mode and penetrance 
information were extracted from online resources for each gene-phenotype pair. 
 
Variants with low quality or high population allele frequencies were filtered out and the 
functional impact was annotated with Variant Effect Predictor (McLaren et al. 2010).  To estimate 
the probability that a variant is damaging to protein function, we integrated multiple prediction 
methods to score all types of variants, e.g. missense, nonsense, indels and intronic variants.  The 
damaging scores were scaled and normalized to reflect the relative deleteriousness, e.g. frame-shift 
/ nonsense variants would have higher scores than missense variants.  We then used the damaging 
scores to estimate the probability that each individual has a particular phenotype with a probabilistic 
model, i.e. calculated as the probability that at least one associated gene in the individual causes the 
phenotype.  For a particular gene, the probability the gene causes the phenotype was calculated as 
the probability that the gene is disrupted (taking into account inheritance mode) multiplied by its 
penetrance score.  
 
The confidence level of the prediction was calculated from the distribution of the estimated 
probabilities across phenotypes and across individuals.  Considering the 14 phenotypes are 
Mendelian like diseases, if one individual has high prediction scores across phenotypes, it is more 
likely to be false positive.  Thus high confidence was assigned to individuals with high variability 
across phenotypes. 
 
A more detailed description of this group’s prediction methods is included in the 
Supplementary Information. 
 
Group 61 (Moult) 
The method (implemented in Python) has four modules – Variant annotation, QC (quality 
check), Variant Prioritization, and Probability scoring for the disease.  The modules were executed 
sequentially.  Inputs were the two gVCF files and a gene configuration file containing the genes 
associated with each disease class and their inheritance pattern.  The Varant tool 
(doi:10.5060/D2F47M2C, http://compbio.berkeley.edu/proj/varant) was used to annotate variants 
with: region of occurrence in the genome, allele frequency from ExAC (Consortium et al. 2016), 
predicted pathogenicity based on four methods (Yue et al. 2006; Kumar et al. 2009; Adzhubei et al. 
2013; Kircher et al. 2014) (for missense), and previously reported disease associations in databases 
(Stenson et al. 2003; Landrum et al. 2016).  Three QC analyses were run:  (1) Variant counts 
(common vs. rare vs. novel & homozygous vs. heterozygous) per sample, (2) Read depth for each 
gene in each sample was obtained by averaging DP values over all bases in a gene recorded in the 
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gVCF file, and (3) Exons with relatively low or no coverage compared to other exons in a gene.  The 
QC qualified variants per sample were prioritized by first assigning them to one of three classes, 
ranked by the likelihood that the variant is causative and further grouping the variants in each class 
by frequency based on its ExAC MAF (group 1 – novel, 2 - very rare (MAF <= 0.005), or 3 – rare (MAF 
<= 0.01)..  Class-1 identified variants previously reported in disease databases as pathogenic, Class-2 
identified loss of function, splice and missense variants predicted damaging by in-silico prediction 
tools, and Class-3 identified missense variants (not predicted damaging), UTR, and intronic variants.  
Variants were further filtered for inheritance model.  For each sample, once putative causative 
variants were found, the process was terminated (e.g. if a suitable variant or variants were found 
using Class-1, Class-2 and Class-3 were not executed).   Finally, a probability score for a sample to 
have a particular disease was computed based on the type of prioritized variant(s) and inheritance 
pattern.  For the missense variants, the probability model was based on the extent of consensus 
among the four prediction methods, using a previous HGMD derived calibration.  For other variant 
types, subjective probability rules were used. 
 
 
 
Results 
Summary of submissions 
Five groups submitted predictions (with 4, 2, 2, 2, and 1 distinct predictions per group).  An 
overview of the challenge and results is shown in Figure 1.  The 106 patients in the challenge can be 
roughly grouped into two difficulty classes:  1) patients for whom Hopkins noted a potentially causal 
variant in the answer key (43 patients) and 2) patients for whom Hopkins did not note any variants 
(63 patients) (Figure 1A).  At least one CAGI-4 predicting group correctly predicted the disease class 
for 36 of the 43 patients who had a reported variant (Figure 1B).  Fewer groups correctly predicted 
both the disease class and at least one of the variant(s) that Hopkins reported (Figure 1C).  CAGI-4 
predictors were not as accurate at predicting disease classes for the remaining 63 patients for whom 
Hopkins did not note a variant, although at least one group correctly predicted the disease class for 
the majority of these patients (Figure 1D).  The lower prediction accuracy is perhaps unsurprising 
given the negative test results for these 63 patients. 
 
Numeric assessment summary 
Table 2 summarizes our numeric assessment metrics for each non-redundant, submitted 
prediction, for all patients.  Table 3 shows the same statistics for only the 43 patients for which 
Hopkins noted at least one potentially causal variant.  The best values for each metric in each table 
are indicated in bold.  Each group’s overall performance is briefly discussed below. 
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Table 4 shows a summary of the performance of all predicting groups on each patient.  An 
expanded version of Table 4 with additional columns is provided as Supplementary Information 
(Supp. Table S-6).  Tables 5 and 6 summarize the most frequent combinations of groups that 
predicted the correct disease class for patients (Table 5 ignores causal variant predictions, while 
Table 6 requires each group to predict one of the variants noted by Hopkins). 
 
Group 57 (Jones) – Group 57’s primary submission (57.1) scored much higher than their other 
submissions by our metrics.  Their method was less accurate than other groups in cases where 
Hopkins reported a potential causal variant, but it was more accurate at predicting the correct 
disease class in cases where Hopkins didn’t report a variant.  Group 57’s primary submission was 
also the most accurate among all submissions at rank-ordering the disease classes.  As seen in Table 
5, Group 57 predicted disease classes correctly for 18 patients that no other group predicted 
correctly, with seven of these cases in their primary submission. 
 
This method was unique in that it did not attempt to mimic a traditional clinical genetics 
approach.  No attempt was made to independently predict the pathogenicity of the ClinVar variants 
used as features or to correct for linkage disequilibrium, which may explain why the method was 
able to make correct inferences where no causal variants were reported and why correct inference 
can arise without reporting the correct variants.  A possibility is that some or even a majority of the 
variants relied on by the classifiers were non-causal variants which simply happen to be in linkage 
disequilibrium with one or more true causal variants.  Thus the occurrence of these variants were 
sufficient to identify the sample as a genetic outlier, though not indicating true causation.  It is 
possible that by addressing these issues, the method might be further enhanced to make more 
accurate predictions relating to true causal variants.  It would be interesting to test this method on a 
larger dataset to rule out the possibility that there is some underlying structure in this dataset that 
the algorithm is detecting. 
 
Group 58 (Tosatto) – As seen in Table 5, most cases that Group 58 predicted correctly were also 
predicted by at least one other group.  However, Group 58 predicted the disease class for one 
patient (P81) that no other groups predicted; they also assigned 100% probability of the correct 
disease to that patient, and predicted exactly the same causal variants as noted by Hopkins. Many of 
the diseases in this challenge result from loss of function variants in a given gene, thus by excluding 
frameshift variants (out of frame deletions and/or insertions within an exon) Group 58 missed these 
cases. The genes and molecular mechanisms associated with each of the 14 disease classes were not 
provided as part of the dataset, which increased the difficulty of the matching exercise (Supp. Table 
S-2). 
 
Group 59 (Qiagen) – Group 59 had the highest average P values for the correct disease classes, after 
normalization; they also had some of the best scores in the avgError metric.  Group 59 correctly 
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predicted the disease class for five patients that no other groups predicted.  Among all the groups, 
they were the only group for which both P values and SD values were independent and positively 
correlated with the values they were expected to correlate with (see discussion of P and SD, below).  
This challenge was well-suited for the Qiagen group, as they specialize in large scale variant 
interpretation (Tricarico et al., 2017). 
 
Group 60 (RSS) – Due to the misleading fields in the combined VCF files (see the Methods section on 
sequencing and variant calling), Group 60 made only 11 high-confidence (P > 0.6) predictions, of 
which 9 were correct.  Interestingly, four of these nine cases were not predicted correctly by any 
other group.  Because of the small number of high-confidence predictions, Group 60 had the lowest 
avgError score among all groups, and the best correlation between assigned P values and correct 
answers (see discussion of P and SD, below).  After the challenge closed, Group 60 provided the CAGI 
organizers with a corrected submission, in which the misleading VCF fields were ignored.  In this 
corrected submission (which arrived late and therefore was not formally assessed), Group 60 
correctly predicted 38 disease classes.  Additional analysis of Group 60’s corrected submission is 
provided in the Supplementary Information.  Group 60 adeptly used a series of online clinical 
genetics resources in their analysis pipeline. 
 
Group 61 (Moult) – Group 61 made more correct predictions of both disease class and Hopkins-
annotated variants than any other group.  For the 43 cases where Hopkins noted variants, Group 61 
did especially well, getting 26 disease classes correct, and predicting the best average rank for the 
correct disease.  In 25 of these cases, Group 61 also predicted at least one causal variant that was 
noted by Hopkins.  Group 61 correctly predicted the disease class for six patients that no other 
groups predicted correctly, and also predicted at least one of the potentially causal variants noted by 
Hopkins in four of these six cases. 
 
Accuracy of P and SD values 
We expected that predictors’ submitted probabilities for each patient and disease should 
correlate with the correct disease class for each patient, and we also expected that their submitted 
standard deviations on each prediction should correlate with the error in each prediction (i.e., the 
absolute difference between the P value and either 1 or 0, for cases where the patient does or does 
not have the disease, respectively).  Overall, predictors did better in the first case, and not as well in 
the second.  Only one group (59; Qiagen) had an independent SD model that correlated positively 
with error.  A detailed discussion of the accuracy of P and SD predictions is provided in the 
Supplementary Information. 
Commentary on novel variant predictions 
 One large limitation in the design of this challenge is that only a subset of the sequence data 
were clinically analyzed in each patient.  This allowed for the possiblity of false negatives, where true 
pathogenic variants may have been present in genes that were not analyzed by the lab.  Further, 
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Internal Review Board (IRB) restrictions prevented the data provider from acting as an assessor for 
the challenge or providing detailed feedback on variant predictions in genes that were not clinically 
analyzed.  In addition, specific variants cannot be listed in the following discussion.  In the future, 
advanced planning is needed to ensure that the appropriate consents and approvals are in place to 
maximize the use of clinical data.  Ideally, a dataset should be fully analyzed by a clinical lab and 
patients should be specifically asked for consent that their data be used for research purposes such 
as the CAGI challenge.  This would allow a more critical analysis of the challenge data, would 
eliminate the possibility of unwanted incidental findings, and would allow more in-depth discussion 
of challenge results.  Clinical data from human patients makes an interesting challenge set, but data 
from human subjects involve privacy concerns vastly different from that of laboratory model 
organisms. 
 
The CAGI-4 Hopkins clinical panel challenge gives us an opportunity to test state-of-the-art 
genetic analysis pipelines on a subset of the data that would be obtained from complete exome 
sequencing of patients, and to explore potential advantages and disadvantages of genomics-driven 
approaches to clinical testing versus the phenotype-driven approach currently employed by Hopkins.  
In some cases multiple groups reported the same causal variant for a case where Hopkins did not 
identify a variant.  Since Hopkins only analyzed the genes ordered by the physician, it is possible that 
there were true pathogenic variants identified in the challenge that were not included on the answer 
key, such cases are elaborated on below.   In order to explore the potential complication of false 
positives in the genomics-driven approach, we also examined cases in which CAGI-4 predictors 
consistently predicted the wrong disease class along with the same causal variants.  Several of these 
cases are described below: 
 
Patient P7 – Groups 57 (submission 4), 58, 59, and 61 all predicted Telomere Shortening Disorders, 
and the latter 3 groups consistently noted a missense variant in TERT.  The patient’s diagnosis was 
Cystic Fibrosis and CF-Related disorders, and Hopkins did not note any reportable variants and did 
not analyze the TERT gene. The TERT variant is described in the literature; it leads to telomere 
shortening and is involved in bone marrow failure.  Telomere shortening due to mutations in TERT is 
known to be involved in pulmonary fibrosis.  Clinical presentation of pulmonary fibrosis is very 
different from cystic fibrosis.  This TERT variant is annotated in ClinVar as involved in pulmonary 
fibrosis, but literature support for this phenotype is unclear.  The variant is found in 120 ExAC 
participants including 2 homozygotes.  
 
Patient P36 – Groups 57 (submission 2), 58, 59, and 61 all predicted Liddle syndrome, with the same 
missense variant in SCNN1G.  The patient’s diagnosis was Diffuse Lung Disease.  The SCNN1G variant 
is a known pathogenic variant observed in two independent patients with bronchiectasis.  The 
predictors presumably predicted Liddle syndrome because the same gene is involved in that 
disorder.  This is likely an example of another false positive prediction common to multiple groups.  
Hopkins did not note a reportable variant for this patient and the SCNN1G gene was not analyzed. 
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Patient P37 – Groups 57 (submission 2), 58, 59, and 61 all predicted Marfan syndrome with the 
same variant, a missense variant in FBN1.  The patient’s diagnosis was Diffuse Lung Disease. FBN1 is 
involved in Marfan syndrome and in other cardiac phenotypes.  A subgroup of Marfan patients 
develop lung emphysema, which is possibly a reason for the predictions.  The missense variant is a 
known low frequency polymorphism annotated as “benign” in ClinVar, so this is likely a false positive 
prediction.  Hopkins did not note any variants for this patient and did not analyze the FBN1 gene. 
 
Patient P14 – Groups 57 (submissions 3 and 4), 58, 59, and 61 all predicted Cystic Fibrosis and CF-
Related disorders, along with one to two out of four variants in CFTR.  The patient’s diagnosis was 
Diffuse Lung Disease, and Hopkins did not analyze the CFTR gene.  All the predicted CFTR variants 
have previously been reported.  One is a common polymorphism, and unlikely to contribute to 
disease.  Another is intronic, and it is not clear whether it may be involved in splicing.  The remaining 
two CFTR variants were rare missense variants.  One missense variant is seen in ExAC 739 times 
including once in the homozygous state, and there is no information on its pathogenicity reported in 
the literature or public databases.  The second missense variant is seen in ExAC 623 times including 
once in the homozygous state, and there is conflicting evidence reported in the literature regarding 
its pathogenicity.  The latter two variants appear to be too common to be causal in this case, but as 
mentioned above, CF studies may be included in ExAC.  It would be prudent to study the background 
frequencies of these two variants in further detail, in order to decide whether they are likely to be 
causative. 
 
 
 
Discussion 
Overall, we found that current state of the art computational prediction methods do a 
reasonable job of predicting clinical phenotype from genotype, even when blinded to clinical 
diagnoses.  At the same time, current genotype-driven prediction methodologies generate false 
positives and false negatives at a rate unacceptable for clinical use.  In cases where the Hopkins lab 
reported a variant, predictors did relatively well, with at least one group correctly identifying the 
disease class in 36 of 43 patients (84%), and at least one group identifying the correct disease class 
and variant in 33 of 43 cases (77%).  In cases where the Hopkins lab did not find a reportable variant 
in the genes they analyzed, at least one group correctly matching the disease class in 39 of 63 
patients (62%).  In the latter cases, methods based on machine learning (SVM) technology appeared 
to be most effective at correctly identifying the disease.  Interestingly, despite the ability to correctly 
match genotype to phenotype, the SVM-based method could not correctly identify the pathogenic 
variant.  It is unclear what is happening in cases where groups correctly identify the disease class, 
but not the causal variant. In retrospect, it would have been prudent to include a list of gene-disease 
associations as well as modes of inheritance to the predictors to aid in the matching process.  
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Different groups performed better depending on which metric was used; there was no clear 
“winner” that dominated performance across all metrics.  Indeed, every group predicted at least one 
patient’s disease class correctly that no other group predicted correctly.  This result suggests that a 
“meta-predictor” or a human clinical expert with access to all groups’ results might improve on the 
performance of each individual group. 
 
Currently, clinical genetic testing is almost entirely phenotype-driven:  given a clinical 
diagnosis, laboratories analyze variants in genes known to be relevant to the diagnosed disease.  
This is partially due to the historic technical limitations on genetic testing, e.g., sequencing costs 
limited the number of genes for which data could be obtained.  The standards for reporting variants 
to the patient are also currently conservative, in part because common, benign polymorphic variants 
have caused many false positives in past genetic analyses (Manrai et al. 2016, Walsh et al. 2017).  
However, as whole-exome and whole-genome sequencing become more economical, the 
phenotype-driven paradigm may be replaced by a genomics-driven approach, in which all rare, 
putatively functional variants in a patient’s genome are first identified, then evaluated based on the 
plausibility that they may be pathogenic.  The genomics-driven approach has the potential for higher 
sensitivity, due to more genes being analyzed, and also has the potential to diagnose diseases not 
identified by the referring physician.  However, the main tradeoff compared to phenotype-driven 
approaches is a potentially higher false positive rate. 
 
Multiple CAGI-4 groups in the Hopkins challenge were in consensus in identifying several 
possible causative variants that were not identified by the current panel testing paradigm.  They also 
identified several other variants that were likely to be false positives.  Distinguishing these two 
possibilities, and identifying which variants to report to the patient, is a topic that requires further 
research.  The American College of Medical Genetics and Genomics has published guidelines for the 
interpretation of sequence variants in order to help codify variant assessment (Richards et al. 2015).  
However, even when adhering to these guidelines there are still elements of variant interpretation 
that are subjective and vary between labs (Amendola et al. 2016, Garber et al. 2016).  Given large 
databases of “control” exomes (i.e., without a known phenotype), researchers could develop 
statistical models to predict whether particular variants are in fact causative (Consortium et al. 
2016).  Such models could inform the development of new statistically justified reporting standards 
based on, for example, particular thresholds on the probability that the prediction of a causal variant 
is a false positive. 
 
This challenge was designed to reflect the range of cases seen in the Hopkins diagnostic lab 
(Figure 1A).  This includes a high percentage of cases for which no likely pathogenic variant was 
identified, despite the patient presenting with a clinical phenotype.  Even for clinical exome 
sequencing, nearly 75% of cases are negative (Lee et al. 2014, Posey et al. 2016).  Negative cases 
proved especially challenging to participants, as ‘phenotype not discernable’ was not listed as a 
matching option.  Despite the fact that no pathogenic variants were identified by the Hopkins lab, 
most groups were able to make a disease prediction and to identify putative pathogenic alleles in 
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these negative cases.  Indeed, the reason data from all 83 genes was included in the challenge was 
to highlight the difficulty in interpreting a large data set of rare variants that are unrelated to the 
patient’s phenotype.  The presence of negative cases in the data set reflects clinical practice and 
cautions on the overinterpretation of rare variants. 
 
Unlike prior prediction challenges, where the activity of an enzyme had been quantitatively 
measured in the laboratory, there was no definitive answer key for this challenge. The predictors 
were asked to match sequencing data to a phenotype, and many groups did so by first identifying a 
causative variant. Only in a minority of cases (~23% in this dataset) could it be said with high 
confidence that a variant was likely contributing to disease in a patient.  When a clinical laboratory 
reports a variant as Pathogenic, this is often because the variant has previously been reported in 
patients with the same phenotype or the nucleotide change introduces a premature termination 
codon in a gene where loss-of-function variants cause disease (Richards et al. 2015).  Thus, with a 
foundation in clinical genetics and access to online resources one could identify a large proportion of 
the ‘Pathogenic’ variants in this dataset.  However, many of the variants detected in the clinical 
laboratory are rare missense or synonymous variants that have not previously been reported in the 
literature; these are almost always classified as variants of uncertain clinical significance.  It is for 
these variants of uncertain significance, that are difficult to interpret and for which there is no 
answer key, that better assessment tools are needed. 
 
A CAGI challenge focused on the interpretation of variants of uncertain clinical significance 
would be more relevant to current clinical genetics practice.  A clinical lab may upgrade a variant’s 
classification from ‘Uncertain’ to ‘Pathogenic’ based on new clinical information, segregation of a 
variant within a family, or identification of the variant in multiple unrelated individuals.  Many 
molecular diagnostic labs maintain internal variant databases; such databases could be mined to 
curate a challenge set of ‘Uncertain’ variants for which there is unpublished data to support 
pathogenicity.  In this proposed challenge, participants would have to correctly identify these 
‘Pathogenic’ variants from a set of ‘Uncertain’ variants (for which there was unpublished data that 
they were NOT likely to contribute to disease).  This would more directly test the challengers’ ability 
to predict pathogenicity without relying on allele frequency or online databases and without 
requiring knowledge of gene-disease associations.  Assessment of the challenge would benefit from 
having fully vetted data and a clear answer key.  This type of challenge, while still lacking a 
phenotype component, would more accurately mirror the clinical challenge of interpreting rare 
variants.  Obtaining this data set would also invite communication between clinical testing labs (both 
academic and commercial) and the research community.    
 
In this vein, the development of a clinically useful variant assessment tool will require 
collaboration between clinical geneticists and data scientists.  Discussions resulting from the Hopkins 
Clinical challenge demonstrated that although most participants incorporated genetic principles into 
their pipelines, they approached variant interpretation in a very different manner than a clinical 
laboratory.  In future challenges, it would be interesting to pair an informatics group with a clinical 
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group as a challenge team, particularly for whole exome sequencing challenges.  Ideally, the back-
and-forth between clinical and informatics groups would produce a method that could outperform 
that of either group alone.  Diverse collaborations at CAGI could help bridge the communication gap 
between fields and pave the way for development of better tools.  
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Figure Legends 
 
Figure 1.  Summary of CAGI-4 Hopkins clinical panel challenge and results.  A) 106 patients were 
included in the study.  Hopkins noted at least one variant relevant to the disease class for which the 
patient was referred in 43 cases, and did not note a variant for the remaining 63 cases. Hopkins 
noted variants of the following classes: Variant of Uncertain Significance, Likely Pathogenic or 
Pathogenic.  Clinically, Hopkins would have reported 25/43 as Positive and 18/43 as Uncertain.  B)  
Among the 43 patients for whom Hopkins had noted a variant, at least one CAGI-4 prediction group 
predicted the correct disease class in 36 cases, and one patient’s disease class was predicted 
correctly by all 5 groups.  C) Among the 43 patients for whom Hopkins had noted a variant, at least 
one CAGI-4 prediction group predicted both the correct disease class and a causal variant noted by 
Hopkins in 32 cases.  D) The 63 patients for whom Hopkins did not note a variant were more difficult 
for CAGI-4 groups to predict:  24 were not predicted correctly by any group, and only 5 patients’ 
disease class was predicted correctly by 3 groups (none were predicted correctly by 4 or more 
groups). 
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Table 1: Disease Classes.  This is a summary of the 14 disease classes in the CAGI-4 Hopkins clinical 
panel challenge. 
Disease Class Description 
Cystic Fibrosis and CF-
Related Disorders 
Classic Cystic Fibrosis (CF) consists of progressive lung disease, exocrine pancreatic 
insufficiency and male infertility. 
Diffuse Lung Disease Diffuse lung disease is an umbrella term encompassing multiple lung disease 
phenotypes. 
Primary Ciliary Dyskinesia Primary Ciliary Dyskinesia is a genetically heterogeneous group of disorders 
resulting from dysfunction in different parts of the cilia.  
Peroxisomal Beta-Oxidation 
Defects 
The majority of patients with peroxisomal betaoxidation defects have liver 
disease, brain malformations, developmental retardation, sensory deficits and 
dysmorphic craniofacial features. 
Rhizomelic Chondrodysplasia 
Punctata 
Symptoms of Rhizomelic Chondroplasia Punctata (RCDP) include proximal 
shortening of the limbs, cataracts, severe intellectual disability, seizures and 
calcific stippling of cartilage. 
Zellweger Spectrum 
Disorders 
Zellweger spectrum disorders (ZSD) consist of Zellweger syndrome (cerebro-
hepato-renal syndrome; most severe phenotype), neonatal adrenoleukodystrophy 
(NALD; intermediate phenotype) and infantile Refsum disease (IRD; mildest 
phenotype). 
Loeys-Dietz Syndrome Loeys-Dietz syndrome (LDS) is a connective tissue disorder that predisposes 
individuals to aortic aneurysms. 
Marfan Syndrome Marfan syndrome (MFS) is an inherited connective tissue disorder that affects the 
skeletal, ocular and cardiovascular systems. 
Thoracic Aortic Aneurysm 
and Dissection 
Thoracic Aortic Aneurysm and Dissection (TAAD) is a cardiovascular disease 
characterized by dilation of the aorta, which leads to aortic aneurysms (most 
commonly in the ascending aorta) and aortic dissection. 
Ataxia Telangiectasia Ataxia-Telangiectasia (A-T) is a disorder of childhood onset progressive cerebellar 
ataxia and occulocutaneous telangiectasias. 
Liddle Syndrome Liddle syndrome is a rare genetic disorder characterized by early onset high blood 
pressure (hypertension) and low blood potassium (hypokalemia). 
Pseudohypoaldosteronism 
Type 1 
Pseudohypoaldosteronism Type 1 (PHA1) is a saltwasting disease with onset 
during infancy. 
Telomere Shortening 
Disorders 
Telomere shortening disorders represent a spectrum of phenotypes that result 
from mutations in genes involved in telomere maintenance protein complexes. 
Treacher Collins and Related 
Syndromes 
Treacher Collins syndrome is a rare disorder affecting craniofacial development. 
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Table 2: Summary of assessment metrics for each non-redundant, submitted prediction, for all 
patients.  Predictions are numbered according to the group’s (formerly anonymized) group number 
(57: Jones, 58: Tosatto, 59: Qiagen Bioinformatics, 60: RSS, 61: Moult) and the group’s submission 
number (1 = most confident prediction, other non-redundant predictions are as numbered by the 
submitters, up to five per group). 
 
  
Group Prediction nCorrect nCorrecttie nCorrectvar avgPCorrect avgPCorrectnorm avgRank avgError 
Jones 57.1 24 24 2 0.305 0.098 5.32 0.251 
 57.2 9 9 2 0.239 0.068 7.66 0.287 
 57.3 7 7 0 0.236 0.068 7.78 0.289 
 57.4 7 6.5 0 0.426 0.074 7.1 0.42 
Tosatto 58.1 23 23 13 0.178 0.217 6.48 0.105 
 58.4 26 25 16 0.223 0.227 6.15 0.107 
Qiagen 59.1 32 29.5 19 0.302 0.278 5.82 0.09 
 59.2 31 28.5 19 0.292 0.269 5.88 0.091 
RSS 60.1 12 12 8 0.072 0.102 7.14 0.08 
 60.2 12 12 8 0.068 0.094 7.15 0.082 
Moult 61.1 38 34.99 25 0.261 0.265 5.65 0.105 
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Table 3: Summary of assessment metrics for each non-redundant, submitted prediction, for the 43 
patients for which Hopkins noted at least one potentially causal variant.  Predictions are numbered 
as in Table 2. 
Group Prediction nCorrect nCorrecttie nCorrectvar avgPCorrect avgPCorrectnorm avgRank avgError 
Jones 57.1 5 5 2 0.255 0.082 6.53 0.257 
 57.2 5 5 2 0.325 0.091 6.29 0.274 
 57.3 2 2 0 0.22 0.063 8.49 0.296 
 57.4 1 1 0 0.394 0.07 7.5 0.421 
Tosatto 58.1 15 15 13 0.32 0.349 5.56 0.087 
 58.4 17 16 16 0.38 0.339 5.16 0.094 
Qiagen 59.1 23 21 19 0.535 0.488 4.24 0.065 
 59.2 22 20 19 0.512 0.465 4.4 0.066 
RSS 60.1 9 9 8 0.149 0.193 6.41 0.073 
 60.2 9 9 8 0.145 0.181 6.4 0.075 
Moult 61.1 26 26 25 0.5 0.512 3.78 0.07 
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Table 4: Summary of the performance of all predicting groups on each patient.  An expanded version 
of Table 4 with additional columns is provided as Supplementary Information (Table S-6). Columns in 
Table 4 are: 
1) nC – Number of groups predicting the disease class correctly, among all submissions 
from each group (counting ties, except in cases where all 14 disease classes were 
assigned equal probability) 
2) nCV – Number of groups predicting both the correct disease class and at least one 
variant noted by Hopkins 
3) correct groups – a list of groups in which the disease class was predicted correctly in 
at least one submission (counting ties, except in cases where all 14 disease classes 
were assigned equal probability).  Groups are numbered as in Table 2. 
4) correct groups, with variant – a list of groups with at least one prediction of the 
correct disease class, and also at least one variant noted by Hopkins (N/A in this field 
indicates that Hopkins did not note any variants).  Predictions are numbered as in 
Table 2. 
5 and 6)  correct predictions (with variant) – same as above, but indicating individual submission 
numbers that were correct. 
Pa-
tient 
nC nCV correct 
groups 
correct groups, with 
variant 
correct predictions correct predictions, with 
variant 
P1 4 4 57, 59, 60, 
61 
57, 59, 60, 61 59.2, 60.1, 60.2, 61.1, 57.1, 57.3, 
59.1 
59.2, 60.1, 60.2, 61.1, 57.1, 
59.1 
P2 1 N/A 57 N/A 57.2 N/A 
P3 0 N/A None N/A None N/A 
P4 5 3 57, 58, 59, 
60, 61 
58, 59, 61 59.2, 58.4, 60.1, 60.2, 61.1, 57.1, 
58.1, 59.1 
59.2, 58.4, 61.1, 58.1, 59.1 
P5 2 2 60, 61 60, 61 60.1, 60.2, 61.1 60.1, 60.2, 61.1 
P6 3 N/A 57, 59, 61 N/A 59.2, 61.1, 57.1, 59.1 N/A 
P7 0 N/A None N/A None N/A 
P8 1 1 60 60 60.1, 60.2 60.1, 60.2 
P9 1 0 57 None 57.4, 57.1 None 
P10 2 N/A 57, 58 N/A 58.4, 57.1, 58.1 N/A 
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P11 1 1 61 61 61.1 61.1 
P12 0 N/A None N/A None N/A 
P13 3 N/A 57, 58, 60 N/A 57.4, 58.4, 60.1, 60.2, 57.2, 58.1 N/A 
P14 0 N/A None N/A None N/A 
P15 0 N/A None N/A None N/A 
P16 2 N/A 57, 58 N/A 58.4, 57.1, 58.1 N/A 
P17 3 3 58, 59, 61 58, 59, 61 59.2, 58.4, 61.1, 58.1, 59.1 59.2, 58.4, 61.1, 58.1, 59.1 
P18 2 N/A 57, 58 N/A 58.4, 57.1, 58.1 N/A 
P19 1 1 60 60 60.1, 60.2 60.1, 60.2 
P20 1 N/A 57 N/A 57.1 N/A 
P21 1 N/A 57 N/A 57.1 N/A 
P22 1 N/A 59 N/A 59.2, 59.1 N/A 
P23 0 0 None None None None 
P24 4 3 57, 58, 59, 
61 
58, 59, 61 59.2, 58.4, 61.1, 57.2, 58.1, 59.1 59.2, 58.4, 61.1, 58.1, 59.1 
P25 1 0 57 None 57.2 None 
P26 3 3 58, 59, 61 58, 59, 61 59.2, 58.4, 61.1, 59.1 59.2, 58.4, 61.1, 59.1 
P27 3 1 58, 59, 61 59 59.2, 58.4, 61.1, 58.1, 59.1 59.2, 59.1 
P28 2 N/A 57, 59 N/A 59.2, 57.1, 59.1 N/A 
P29 1 N/A 57 N/A 57.1 N/A 
P30 3 2 58, 59, 61 58, 61 58.4, 61.1, 58.1, 59.1 58.4, 61.1, 58.1 
P31 1 N/A 57 N/A 57.1 N/A 
P32 4 3 58, 59, 60, 
61 
58, 60, 61 59.2, 58.4, 60.1, 60.2, 61.1, 58.1, 
59.1 
58.4, 60.1, 60.2, 61.1, 58.1 
P33 0 N/A  N/A None N/A 
P34 3 3 58, 59, 61 58, 59, 61 59.2, 58.4, 61.1, 58.1, 59.1 59.2, 58.4, 61.1, 58.1, 59.1 
P35 0 N/A None N/A None N/A 
P36 0 0 None None None None 
P37 0 0 None N/A None N/A 
P38 3 3 58, 60, 61 58, 60, 61 58.4, 60.1, 60.2, 61.1, 58.1 58.4, 60.1, 60.2, 61.1, 58.1 
P39 1 0 59 None 59.2, 59.1 None 
P40 0 N/A None N/A None N/A 
P41 0 N/A None N/A None N/A 
P42 2 1 59, 61 61 59.2, 61.1, 59.1 61.1 
P43 2 N/A 57, 61 N/A 61.1, 57.1 N/A 
P44 1 N/A 59 N/A 59.2, 59.1 N/A 
P45 1 N/A 57 N/A 57.1 N/A 
P46 0 N/A None N/A None N/A 
P47 1 1 61 61 61.1 61.1 
P48 0 0 None None None None 
P49 1 N/A 57 N/A 57.1 N/A 
P50 0 N/A None N/A None N/A 
P51 1 N/A 61 N/A 61.1 N/A 
P52 3 3 58, 59, 61 58, 59, 61 59.2, 58.4, 61.1, 59.1 59.2, 58.4, 61.1, 59.1 
P53 2 N/A 58, 59 N/A 59.2, 58.4, 58.1, 59.1 N/A 
P54 1 N/A 57 N/A 57.3 N/A 
P55 0 0 None None None None 
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P56 2 1 58, 59 59 59.2, 58.1, 59.1 59.2, 59.1 
P57 1 1 61 61 61.1 61.1 
P58 0 N/A None N/A None N/A 
P59 0 0 None None None None 
P60 2 2 59, 61 59, 61 59.2, 61.1, 59.1 59.2, 61.1, 59.1 
P61 1 N/A 57 N/A 57.4, 57.3 N/A 
P62 2 N/A 57, 60 N/A 60.1, 60.2, 57.1 N/A 
P63 3 N/A 57, 59, 61 N/A 59.2, 61.1, 57.1, 59.1 N/A 
P64 1 1 60 60 60.1, 60.2 60.1, 60.2 
P65 3 N/A 58, 60, 61 N/A 58.4, 60.1, 60.2, 61.1 N/A 
P66 0 N/A None N/A None N/A 
P67 0 0 None None None None 
P68 1 N/A 59 N/A 59.2, 59.1 N/A 
P69 0 0 None None None None 
P70 0 N/A None N/A None N/A 
P71 0 N/A None N/A None N/A 
P72 3 2 57, 59, 61 59, 61 59.2, 61.1, 57.2, 59.1 59.2, 61.1, 59.1 
P73 4 3 57, 58, 59, 
61 
58, 59, 61 59.2, 58.4, 61.1, 57.1, 58.1, 59.1 59.2, 58.4, 61.1, 58.1, 59.1 
P74 0 N/A None N/A None N/A 
P75 0 N/A None N/A None N/A 
P76 0 N/A None N/A None N/A 
P77 0 N/A None N/A None N/A 
P78 1 N/A 61 N/A 61.1 N/A 
P79 0 N/A None N/A None N/A 
P80 3 3 57, 59, 61 57, 59, 61 59.2, 61.1, 57.1, 57.2, 59.1 59.2, 61.1, 57.1, 57.2, 59.1 
P81 1 1 58 58 58.4, 58.1 58.4, 58.1 
P82 1 N/A 57 N/A 57.2 N/A 
P83 1 N/A 57 N/A 57.4, 57.3 N/A 
P84 4 4 57, 58, 59, 
61 
57, 58, 59, 61 59.2, 58.4, 61.1, 57.2, 58.1, 59.1 59.2, 58.4, 61.1, 57.2, 58.1, 
59.1 
P85 2 N/A 57, 61 N/A 57.4, 61.1 N/A 
P86 2 N/A 58, 59 N/A 59.2, 58.4, 58.1, 59.1 N/A 
P87 3 N/A 57, 58, 61 N/A 57.4, 58.4, 61.1, 57.1, 58.1, 57.3 N/A 
P88 1 N/A 57 N/A 57.1 N/A 
P89 1 N/A 57 N/A 57.4, 57.1 N/A 
P90 2 N/A 58, 61 N/A 58.4, 61.1, 58.1 N/A 
P91 1 N/A 57 N/A 57.2 N/A 
P92 3 3 58, 59, 61 58, 59, 61 59.2, 58.4, 61.1, 59.1 59.2, 58.4, 61.1, 59.1 
P93 1 1 60 60 60.1, 60.2 60.1, 60.2 
P94 2 2 59, 61 59, 61 59.2, 61.1, 59.1 59.2, 61.1, 59.1 
P95 3 3 58, 59, 61 58, 59, 61 59.2, 58.4, 61.1, 58.1, 59.1 59.2, 58.4, 61.1, 58.1, 59.1 
P96 1 0 57 None 57.3 None 
P97 0 N/A None N/A None N/A 
P98 2 N/A 57, 61 N/A 61.1, 57.1 N/A 
P99 1 N/A 59 N/A 59.2, 59.1 N/A 
P100 0 N/A None N/A None N/A 
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P101 2 N/A 57, 61 N/A 61.1, 57.1 N/A 
P102 1 N/A 57 N/A 57.3 N/A 
P103 0 N/A None N/A None N/A 
P104 3 3 58, 59, 61 58, 59, 61 59.2, 58.4, 61.1, 58.1, 59.1 59.2, 58.4, 61.1, 58.1, 59.1 
P105 3 3 58, 59, 61 58, 59, 61 59.2, 58.4, 61.1, 58.1, 59.1 59.2, 58.4, 61.1, 58.1, 59.1 
P106 1 N/A 61 N/A 61.1 N/A 
 
Table 5: Frequency with which each combination of groups correctly diagnosed patients.  This table 
summarizes the number of times each combination of groups correctly diagnosed patients, as shown 
in the “correct groups” column of Table 4. 
Number of patients Groups predicting correct disease class 
31 No group predicted correct disease 
18 57  (Note: 7 from 57.1) 
10 58, 59, 61 
6 61 
5 59 
4 60 
4 57, 61 
4 57, 59, 61 
3 59, 61 
3 58, 59 
3 57, 58, 59, 61 
3 57, 58 
2 58, 60, 61 
1 60, 61 
1 58, 61 
1 58, 59, 60, 61 
1 58 
1 57, 60 
1 57, 59, 60, 61 
1 57, 59 
1 57, 58, 61 
1 57, 58, 60 
1 57, 58, 59, 60, 61 
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Table 6: Frequency with which each combination of groups correctly diagnosed patients, and also 
noted a Hopkins variant.  This table summarizes the number of times each combination of groups 
correctly diagnosed patients and predicted at least one variant noted by Hopkins, as shown in the 
“correct groups with variant” column of Table 4. 
# of patients Groups predicting correct disease & variant 
63 (Hopkins did not note any variants) 
11 58, 59, 61 
11 (No group predicted disease and variant correctly) 
4 61 
4 60 
3 59, 61 
2 59 
2 58, 60, 61 
1 60, 61 
1 58, 61 
1 58 
1 57, 59, 61 
1 57, 59, 60, 61 
1 57, 58, 59, 61 
 
 
